SCHEMBL2746962

SCHEMBL2746962

COC(=O)c1cccc2cc(Nc3ncnc4cc(OC)c(OC)cc34)ccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.62
▸ RET P07949 5/20 0.61
▸ KIF5B P33176 2/20 0.61
▸ FGFR1 P11362 1/20 0.61
▸ FLT1 P17948 1/20 0.61
▸ CDK2 P24941 1/20 0.61
▸ PIK3R1 P27986 1/20 0.61
▸ EPHB2 P29323 1/20 0.61
▸ TTBK1 Q5TCY1 1/20 0.61
▸ EGFR P00533 8/20 0.61
▸ CLK1 P49759 1/20 0.61
▸ ABCG2 Q9UNQ0 1/20 0.61
▸ NOD1 Q9Y239 1/20 0.60
▸ LCK P06239 1/20 0.60
▸ SRC P12931 2/20 0.59
▸ GAK O14976 1/20 0.58
▸ RIPK2 O43353 1/20 0.58
▸ STK10 O94804 1/20 0.58
▸ FLT3 P36888 1/20 0.58
▸ JAK3 P52333 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5753165 0.96 KDR (0.58) KDRRETKIF5BFGFR1FLT1
SCHEMBL2746015 0.92 KDR (0.62) KDRRETKIF5BFGFR1FLT1
SCHEMBL2747131 0.87 KDR (0.74) KDRRETEGFRMAPK14
SCHEMBL2747187 0.86 KDR (0.71) KDREGFRMAPK14
SCHEMBL4549037 0.86 KDR (0.69) KDRRETKIF5BFGFR1FLT1
SCHEMBL2747392 0.86 KDR (0.69) KDRRETKIF5BFGFR1FLT1
SCHEMBL2747980 0.84 EGFR (0.68) KDRFLT1EGFRLCKSRC
SCHEMBL2748014 0.83 KDR (0.75) KDRFLT1EGFRLCKSRC
SCHEMBL6181200 0.81 EGFR (0.74) KDRRETKIF5BFLT1EPHB2
SCHEMBL4821285 0.81 BRAF (0.71) KDREGFRSRCFLT3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885KIF5B 2850/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885KIF5B 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback